Published dose-response curves of promoters ofmultistage carcinogenesis were selected that met the combined criteria of long study times, multiple doses, and low doses. In rat liver, 12 dose-response studies of7 different promoters (phenobarbital, 2,3,7,8-tetrachlorodibenzo-p-dioxin [TCDDI, clophen A-50 (a polychlorinated biphenyl), a-, i-, and '-hexachlorocyclohexane [HCHJ, and chloroform) were selected. These promoters were studied for 7486 weeks and either altered hepatic foci or hepatic cancer were determined. The doses ranged from 1 ng (TCDD) to 400 mg (chloroform). In mouse skin, 10 dose-response studies of 4 promoters (12P-0e-radecanoylphorbol-13-acetate rIPAJ, anthralin, chrysarobin, and 2,6-di-tert-butyl-4hydroperoxyl-2,5-cyclohexadienone [BHTOOHJ) were selected. In these mouse skin studies the doses ranged from OA25 nmole (TPA) to 20,000 nmole (BHTOOH) per mouse. The length oftime promoters were applied to the skin varied between 15 and 60 weeks. Either skin papillomas or carcinomas were determined. The dose-response relationships are presented on the basis ofmoles of promoter, percentage ofthe fully effective p ing dose, or percentage of the acute oral rat LDso. The degree of concavity of the dose-response curves was determined. The available doseresponse data are critiqued and discussed on the basis offuture research needs for bolk ically based cancer risk asement models.
Introduction
As we learn more about multistage carcinogenesis, more data accumulate on the number of stages and the dose-response relationship of each individual stage. After elucidation of the initiation step of carcinogenesis, promotion ofcarcinogenesis was the second stage of multistep carcinogenesis identified. For decades it has been stated that initiators of carcinogenesis are probably linear in their dose-response relationship (extrapolated below the experimental range), while promoters of carcinogenesis are nonlinear and exhibit thresholds of biological response.
With the development of a mathematical two-stage model of carcinogenesis by Moolgavkar and his co-workers (1), the importance of the dose-response relationships of each of the individual steps of multistage carcinogenesis has become more obvious. Each important biological process in Moolgavkar In this study we have compiled published dose-response relationships for promoters ofcarcinogenesis that meet the multiple criteria ofa) long study times (7-86 weeks), b) multiple doses, and c) low doses selected. Without a long study time, a difference of latency might be mistaken for a difference in potency of the promoter. The resulting dose-response curves from 22 experimental studies of 11 different chemicals are examined on the basis of picomole/kilogram, nmole/mouse, percentage of the maximally promoting dose, and percentage of the acute LD5o.
The dose-response curves were examined for concavity (slope increases with dose in the low-dose range), experimental thresholds, slopes, and plateaus ofbiological effects. This doseresponse study ofpromoters ofcarcinogenesis has utility for both risk assessment and the regulation of environmental chemicals.
Rat Liver Studies Table 1 presents the promoters, dose range, length ofpromotion, initiator, number and type of experimental animals, biological end point, and reference for the 12 selected experimental studies ofpromotion ofcarcinogenesis in rat liver. Although no animal species or target organs were deliberately excluded, the only studies found that simultaneously met the criteria oflong study times, multiple dose, and low doses were conducted in rat liver and mouse skin. After initiation by either diethylnitrosamine (DEN), dimethylnitrosamine (DMN), or N-nitrosomorpholine (NNM), rats were administered various promoters anywhere between 7 and 86 weeks, depending on the individual experimental study (Table 1) . In only two studies, both with aAll foci studies used GGT as a marker with the exception ofone clophen A 50 study (8) , which used ATPase. The Pitot et al. (5) phenobarbital (2, 3) , did the experiment progress to hepatic carcinoma. In the 10 remaining studies, preneoplastic foci were determined. For rat liver, the promoting chemicals were phenobarbital, chloroform, a-, ,-, and y-hexachlorocyclohexane (HCH), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and Clophen A 50 (a polychlorinated biphenyl). The doses ranged from a low of 0.0000001 mg/kg for TCDD to 400 mg/kg for chloroform, about 10 orders of magnitude.
Phenobarbital was given to male Sprague-Dawley rats in doses of 62.5, 125, 250, 500, and 1000 ppm in drinking water by Pereira et al. (2) . Rats (19) (20) (21) (22) (23) per treatment group) were initiated with 80 mg/kg DEN by gavage. After 70 weeks ofphenobarbital promotion, sections of rat liver were examined and classified into four different types ofcarcinomas: trabecular (the most common finding), adenocarcinoma, mixed carcinoma, and poorly differentiated carcinoma. Phenobarbital promotion at 250, 500, and 1000 ppm significantly increased the incidence ofcarcinoma, but the phenobarbital treatment groups at 62.5 and 125 ppm did not (Fig. 1) .
The second study that proceeded all the way to full liver carcinoma was performed by Driver and McLean (3) . Male SPFPorton rats (Wistar derived) were initiated by 15 mg/kg ofDMN.
The animals were switched from a protein-free diet to a diet composed of50% casein to increase mitosisjust before the initiation step. The rats (10 per experimental group) were then exposed to 40, 100, or 1000 ppm phenobarbital in their drinking water for 86 weeks. Hepatocellular carcinoma was diagnosed by loss of normal liver architecture, thickened, irregular liver cell plates, and highly abnormal cellular morphology. Only the animal receiving 1000 ppm phenobarbital showed a statistically elevated incidence ofliver carcinoma compared to the DEN-alone treatment group (Fig. 1) . The two lower doses of 40 and 100 ppm phenobarbital were below the experimental threshold ofresponse ( Fig. 1) (3) .
A third dose-response study with phenobarbital was reported by Kunz et (Fig. 3) as promoters. Fischer 344 rats were subjected to a 70% partial hepatectomy before an oral dose of 10 mg/kg DEN was given. After 26 weeks of promotion, rat liver sections were stained for GGT, ATPase, and glucose 6-phosphatase. Altered hepatic foci were scored using all three markers. Rats promoted by the highest phenobarbital dose (0.05%) were statistically elevated in the number of altered hepatic foci, whereas rats exposed to the lowest dose of phenobarbital (0.001%) actually had a statistically decreased number ofaltered hepatic foci. This is experimental evidence for an antipromotional effect of a known promoter of hepatocarcinogenesis. TCDD showed the same dose-response relationship, as did phenobarbital (5) . At the two lowest doses of0.0001 and 0.001lgckg ofTCDD, the number ofaltered hepatic foci was significantly reduced. Only at the higher dose of 0.1 p/kg did TCDD effectively promote carcinogenesis in this two-step experimental system. The polychlorinated biphenyl mixture Clophen A 50 has been examined by a German group in a series ofthree similar studies (6) (7) (8) . Female Sprague-Dawley rats (4 -6 female rats per treatment group) were initiated with 8 mg/kg ofDEN. The promoting chemical Clophen A 50 was given either three times a week for 11 weeks (6), once a week for 7 weeks (7), or three times a week for 11 weeks (8) . In these three studies the daily dose ranged from 0.1 to 100 mg/kg. In two ofthe studies GGIT foci were scored (6, 7) and in one ATPase was used as a marker (8) . Five to one hundred mg/kg of Clophen A 50 significantly increased the number of altered hepatic foci, but doses below 5 mg/kg did not (Fig. 4) .
The a-, ,-and y-HCH isomers were used in a dose-response study ofpromotion in female Wistar rats (9) (Fig. 5) Figure 7 .
In a related 60-week study, Kruszewski et al. (11 ) used 25, 100, 220, and 440 nmole of chrysarobin in SENCAR mice (30 per treatment group) previously initiated with 25 nmole/mouse of DBMA. This study determined percent papillomas, papillomas per mouse, and percent skin carcinomas at a single 60-week time point (Fig. 8) (11) .
The hydroperoxide metabolite of butylated hydroxytoluene AJA-A was used by Taffe and Kensler (15) were not found after exposure to 0.01 or 0.1 nmole of TPA per mouse. All five higher doses (1-20 nmole/mouse) of TPA promoted skin papillomas (Fig. 7) and carcinomas (Fig. 8) .
DiGiovanni et al. (13) (Fig. 9) . The percentage of mice with carcinomas was determined after 45 weeks of promotion with 6.8 nmole of TPA. Dose-response studies of papillomas were also done with 50, 100, 220, and 880 nmole of anthralin (13) (Fig. 9) and with 50, 100, or 220 nmole of chrysarobin (11) (Fig. 9) . In a subsequent 30 week doseresponse study, DiGiovanni et al. (14) The three compounds vary in molar potency by more than 1000-fold. The dose-response curves are fairly steep for all three compounds, but the TPA and chrysarobin experiments were not carried down to promoter doses that resulted in 0% carcinoma.
Neither of these two studies included a control group in which mice were initiated and then given zero dose of the promoter under study. In contrast, the BHTOOH study contained both an initiated control group given zero dose of the promoter (which had 0% carcinomas) and also a 2000 pmole of BHTOOH per mouse experimental group, which also developed 0% carcinomas. In promoting mouse skin carcinomas, BHTOOH demonstrated an experimental threshold (Fig. 8) .
In CD-1 mice, TPA and chrysarobin gave dose-related curves for papillomas/mouse (Fig. 7) . Very few papillomas were caused by chrysarobin in the CD-1 mouse, and three experimental doses showed no effect whatsoever. Although doses of 10 and 100 pmole of TPA did not induce skin papillomas, higher doses of TPA showed a dose-response curve with a high slope. Only the TPA study included a concurrent control group exposed to the initiator and zero dose of the promoter.
In the more sensitive SENCAR mouse, dose-response curves for papillomas/mouse are available for TPA, anthralin, chrysarobin, and BHTOOH (Fig. 9) . The showed a high slope, with a plateau at about 14 papillomas per mouse. Anthralin and chrysarobin show a lower slope, with indications ofa plateau at about four to six papillomas per mouse, a level substantially below that achieved by TPA (Fig. 9) . BHTOOH was tested in only three doses, and thus the slope of the dose-response curve is not really clear.
Comparison on a Percent LD_. Basis
The promotional potency normalized by the lethality potency ofa chemical shows ifa chemical possesses unusual promotional power without accompanying toxicities. Therefore, Figure 11 shows the number of hepatic foci graphed on the basis ofpercent of the chemicals' LD50/kilogram rather than femtomole/ kilogram. Using this approach TCDD is not a remarkably potent hepatic promoter. Normalized on the basis of acute lethality, 3-HCH is the most potent chemical and chloroform, again, is the least potent. Of the seven promoters, TCDD increased the hepatic foci number to the smallest extent, less than 300% ofcontrol values. Due to lack of LD50 information, the four skin tumor promoters cannot be compared on a percent LD5o basis.
Comparison on a Percentage of Maximally Promoting Dose Basis
To determine if the shape of the promotional dose-response curve is fairly similar between chemicals, the maximally promoting dose of each chemical was used a normalization factor. Figure 12 displays the dose-response curves for hepatic foci number of seven promoters. For each promoter, the dose that produced the maximal promotion is set at 100% on the X-axis. Then the logarithmic X-axis is calibrated as 100, 10 Very low dose studies ofthe three isomers ofHCH in Wistar rats found no protective doses ofHCH (Fig. 9) (9) . At the lowest doses of,3-HCH and -y-HCH, the experimental studies showed increases, though not always statistically significant, of about double the control numbers of hepatic foci. Thus, in the dose range below 10% of the maximally promoting dose, two chemicals (TCDD and phenobarbital) show protective effects (5), but three chemicals (a-, f3-and 7y-HCH) do not (9) .
With respect to other rat liver effects ofTCDD, induction of aryl hydrocarbon hydroxylase activity does not show protective effects at low doses (17) . This study used 10 different doses down to 0.0006 Ag/kg, a level corresponding to only 0.0027 % of the LD50 (17) .
Dose-response relationships in multistage carcinogenesis have been both experimentally studied and much debated (18) (19) (20) (21) . However, in the low-dose region, the amount of experimental information available on chemically induced carcinogenesis is quite limited. Experimental approaches to the issue of dose-response relationships are limited by statistical considerations. To determine with 95 % probability an animal carcinogen that causes 5, 2, 0.1, and 0.001 % cancer requires 59, 149, 2995, and 29,950 experimental animals, respectively (22) . This large number ofexperimental animals is required for equal sample sizes (treated and control) with no tumors in the control group. The largest experimental group ever run was 2109 mice in the National Center for Toxicological Research 2-acetylaminofluorene study (23 However, just because an experimental threshold should exist does not mean that any particular experimental study has located the experimental threshold in the dose-response curve. The demonstration of an experimental threshold does not prove or imply the existence of a more absolute (or nonexperimental) threshold for a chemically induced health effect. The question ofwhether there are absolute thresholds ofbiological response cannot be answered with conventional dose-response experiments. Experimental thresholds are presented in this paper because a) they have been of some use in risk assessment procedures, b) they are a way to describe the dose-response curve in the important low dose region, and c) they show that the limit of sensitivity ofdetecting a biological response for a particular experimental study has been reached.
With cancer as the end point, there is good evidence with both phenobarbital in male rat liver (2,3) (Fig. 1) and BHTOOH in mouse skin (15) (Fig. 10) that experimental thresholds exist. Data ofless strength that support this interpretation include TPA and chrysarobin mouse skin carcinoma data (11, 12) (Fig. 8) ; however, no control group given zero dose ofthe promoter was included in these studies. Although the slope of the dose- aAs the response at all three of the lowest doses was zero, the dose response was evaluated for concavity over the lowest four doses. bAlthough the percent papillomas and papillomas per mouse were numerically higher in the low-dose BHTOOH-treated groups than in controls, this was not a statistically significant difference. *p<0.05. response curve was steep, for both TPA and chrysarobin, the lowest tested doses still had a promotional effect.
With liver foci as the end point, strong evidence for experimental thresholds exists for phenobarbital (5), TCDD (5), Clophen A 50 (6) (7) (8) , and chloroform (6, 10) (Fig. 10) . There was no convincing experimental data for thresholds for altered liver foci demonstrated for and a-, (l-, and 'y-HCH (9) (Fig. 10 ).
For skin papillomas in female SENCAR mice, strong evidence for a threshold exists for BHTOOH (15) and anthralin (13) (Fig.  9) . The TPA (13) and chrysarobin (11 ) data are of less strength. In female CD-1 mice, strong evidence for a threshold in skin papillomas exists for both TPA (12) (two experimental doses with no papillomas) and chrysarobin (14) (three experimental doses with no papillomas) (Fig. 7) . As shown in Tables 3 and 4 , there were 22 cases in which it was considered that promotional experimental thresholds have been demonstrated and 19 cases in which they have not.
Thus, overall there is a sufficient amount and quality of experimental data that argue for an experimental threshold in the dose-response relationship of promoters of multistage carcinogenesis. However, only two mouse skin studies included a control group given zero dose ofthe promoter, and this omission limits the utility of the data in biologically based cancer risk assessment models. Unfortunately, only 5 of22 experiments proceeded all the way to the cancer. These five studies are of phenobarbital (2, 3) , BHTOOH (15) , TPA (12, 13) , and chrysarobin (13) . Usually the available dose-response data on promoters of carcinogenesis are limited to altered hepatic foci and skin papillomas. Overall the best dose-response curves available for biologically based cancer risk assessment modeling are the two rat-liver carcinoma studies with phenobarbital (Fig, 11) .
Concave Dose-Response Curves
A concave curve lies below a straight line connecting experimental points and the control values and has a slope that increases with dose for low doses. To test the concavity of the dose-response curves, data from studies ofthese eleven different chemicals were fit into a quadratic equation containing both a linear and a quadratic dose term. If the coefficient of the quadratic dose term is found to be positive, this is evidence for a concave dose-response curve.
As it is typical for dose-response curves to level off at higher doses, only the lowest possible sets of doses were used. The lowest p + 1 doses were selected, where p is the number of parameters in the model (three for a model with an intercept and two for a model without an intercept). In two CD-1 mouse papilloma data sets (14) , all doses chosen by this selection rule had zero papillomas. These two papilloma data sets were analyzed by incorporating the next higher dose.
Linear regression, weighted by the reciprocal of the squares ofthe estimated standard errors ofthe means at each dose, when they were available, was used to fit quadratic dose-responses to the endpoints, foci/cm2, foci as a fraction oftotal liver volume, foci as a percentage of control levels (minus 100%), and all the papilloma data. Models for the papilloma data and foci expressed as a fraction of control levels were forced through the origin by not including an intercept term. A positive coefficient of the quadratic dose term was deemed statistically significant if the coefficient divided by its standard error was greater than the appropriate t-value for a one-tailed, one (or occasionally, two) degree-of-freedom test. In one case, the residual standard deviation was substantially smaller than the pooled standard error. In that one case the test was based on an estimate ofthe standard error of the quadratic coefficient that used the pooled standard error. Models for tumor prevalence were fit using quasi-likelihood methods to fit generalized linear models to the prevalence data. The standard deviation of residuals from the weighted leastsquare models was compared with the pooled standard error of the mean when it was available to ensure that model fit was adequate.
The results of concavity analysis ofdose-response curves are expressed in Tables 3 (rat liver) and 4 (mouse skin). Linear regression analysis showed evidence for a concave curve for some of the dose-response curves of a-HCH (Table 3) . Statistically significant concavity was found for some of the dose-response curves ofphenobarbital, TCDD, Clophen A 50, TPA, chrysarobin, and BHTOOH (Tables 3 and 4) . Concave dose-response curves were not found for chloroform, 3-HCH, y-HCH, or anthralin (Tables 3 and 4 ). There was some degree of evidence for concavity of dose-response curves for all eight biological end points of promotion in Tables 3 and 4 . As the Driver and McLean (3) phenobarbital rat tumor study could not be mathematically modeled, four experimental studies [phenobarbital (2) , TPA (12) , chrysarobin (11) , and BHTOOH (15) ] that proceeded all the way to tumors can be examined for concavity of dose-response. Of these four studies, three show some concavity in the dose-response curve, but this was statistically significant only in the chrysarobin mouse skin study (11) . For 
Summary
In this review of22 published dose-response studies oftumor promoters, five scientific findings are of particular interest and utility. First, both TPA and chrysarobin show two and three experimental doses, respectively, at which zero papillomas were found. Second, the skin dose-response curves have a high positive slope (a steep curve; e. g., TPA-induced papillomas in SENCAR mice: Fig. 9 ). Third, phenobarbital shows the strongest evidence for a threshold ofpromotion ofcarcinogenesis in rat liver (Fig. 1) organs. We found little dose-response data in experimental organs such as female rat liver (carcinoma studies), male rat liver (foci studies), lung, stomach, intestine, breast; and animals such as male mice, hamsters, guinea pigs, rabbits, cats, and dogs. h) To distinguish between various different models of promotion (e.g., linearity with log dose or linearity with arithmetic dose), it is critical that doses be selected that will provide adequate data to subsequently choose between the various possible mathematical models.
For dose-response curves of promoters of carcinogenesis to be highly useful to biologically based risk assessment models, these eight limitations should be addressed. Future doseresponse research on promoters can assist in the development of biologically based risk assessment models and contribute to scientific regulation of chemicals.
